Your browser doesn't support javascript.
loading
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Chien, Amy Jo; Cockerill, Alyson; Fancourt, Craig; Schmidt, Emmett; Moasser, Mark M; Rugo, Hope S; Melisko, Michelle E; Ko, Andrew H; Kelley, R Katie; Korn, W Michael; Esserman, Laura J; van't Veer, Laura; Yau, Christina; Wolf, Denise M; Munster, Pamela N.
Affiliation
  • Chien AJ; Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA. Jo.chien@ucsf.edu.
  • Cockerill A; Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.
  • Fancourt C; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc, Kenilworth, NJ, USA.
  • Schmidt E; Merck Research Laboratories, North Wales, PA, USA.
  • Moasser MM; Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.
  • Rugo HS; Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.
  • Melisko ME; Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.
  • Ko AH; Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.
  • Kelley RK; Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.
  • Korn WM; Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.
  • Esserman LJ; Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • van't Veer L; Department of Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Sanfrancisco, CA, USA.
  • Yau C; Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Wolf DM; Department of Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Sanfrancisco, CA, USA.
  • Munster PN; Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.
Breast Cancer Res Treat ; 155(3): 521-30, 2016 Feb.
Article in En | MEDLINE | ID: mdl-26875185
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Stomach Neoplasms / Breast Neoplasms / Esophageal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Heterocyclic Compounds, 3-Ring Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2016 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Stomach Neoplasms / Breast Neoplasms / Esophageal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Heterocyclic Compounds, 3-Ring Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2016 Type: Article Affiliation country: United States